Dr. Noriyuki Kasahara from UCSF has been awarded $11.8 million by the California Institute for Regenerative Medicine (CIRM) to target newly diagnosed high-grade gliomas. This groundbreaking clinical trial aims to treat high-grade gliomas, one of the most challenging brain cancers to manage. These aggressive cancers develop in the brain or spinal cord and are notoriously … Continue reading Gene therapy trial tests cancer-killing virus in brain tumors
Month: July 2024
CIRM awards $6 million to advance research for heart attack and heart failure treatments
In a promising development for cardiovascular health, Arjun Deb, MD, a professor of medicine and molecular, cell, and developmental biology at UCLA, has received a $6 million award from the California Institute for Regenerative Medicine (CIRM) to advance his groundbreaking research on heart attack and heart failure treatments. Cardiovascular disease remains the leading cause of … Continue reading CIRM awards $6 million to advance research for heart attack and heart failure treatments
CIRM Welcomes Jonathan Thomas as New President and CEO
The California Institute for Regenerative Medicine (CIRM) is excited to announce the appointment of Jonathan “JT” Thomas, PhD, JD, as our new President and CEO. JT brings extensive experience and a deep commitment to our mission. Previously, he served as the Chair of the Independent Citizens' Oversight Committee (ICOC) for 12 years and, most recently, … Continue reading CIRM Welcomes Jonathan Thomas as New President and CEO
$53 million awarded to fund clinical and translational research
The California Institute for Regenerative Medicine (CIRM) recently awarded $53 million to fund various projects, from its Clinical and Translational programs aimed at preventing heart failure to the advancement of cell therapy for Parkinson’s disease and the targeting of numerous cancers. Two preclinical projects are providing funding for eligible stem cell and gene therapy-based projects … Continue reading $53 million awarded to fund clinical and translational research
Advancing cell therapy research for dry age-related macular degeneration (dry AMD)
The California Institute for Regenerative Medicine (CIRM) granted Luxa Biotechnology a $4 million award to support the ongoing Phase 1/2a study (NCT04627428) of RPESC-RPE-4W transplantation, an innovative therapy for treating dry age-related macular degeneration (dry AMD). The funding will significantly enhance manufacturing and clinical activities in California. Dry AMD is a prevalent eye disorder affecting … Continue reading Advancing cell therapy research for dry age-related macular degeneration (dry AMD)
The Stem Cellar 